

H.pylori Infection as Risk Factor for GIT Bleeding in Haemophilic Patients

Noha M. El Husseiny*, Louis Essac and Mona Al Kassas

Clinical Haematology Unit, Internal Medicine Department, Kasr Al Aini, Faculty of Medicine-Cairo University, Egypt

Article Information

Received date: Nov 21, 2016

Accepted date: Jan10, 2017

Published date: Jan 13, 2017

*Corresponding author

Noha M. El Husseiny, Clinical Haematology Unit, Internal Medicine Department, Kasr-Al-Aini, Faculty of Medicine-Cairo University, Egypt; Email: noha_el_husseiny77@yahoo.com

Distributed under Creative Commons CC-BY 4.0

Abstract

Background: Helicobacter pylori is endemic in Egypt and present a main cause of gastrointestinal bleeding.

Aim: this study is to evaluate the prevalence of H.pylori infection in hemophilic patients, and to assess its impact on gastrointestinal bleeding associated with this infection in such patients.

Methods: we prospectively investigated the prevalence of H.pylori infection in 40 Egyptian patients with Hemophilia -A, -B and VonWillebrand syndrome and 20 normal male subjects was included. Every patient and control subject in the study was tested one time for H.pylori stool antigen by ELISA. All patients and control subjects were tested for occult blood using Guaiac-based fecal occult blood test. Results: Twenty eight out of 40 patients (70%) are H. pylori positive; and 12 out of 20 controls (60%) are H. pylori positive. The odds ratio is 1.55, 95% CI (0.6162 to 3.9269), Significance level P=0.3497. Among 28 H.pylori positive patients, 5 patients (17.9 %) tested positive for occult blood. Among the 12 H.pylori positive subjects in the control group, only one tested positive for occult blood (8.3%). Odds ratio for Occult bleeding in H pylori positive patients and control was 2.39: P=0.4504. None of the H.pylori negative patients or control subjects had a positive occult blood disease. Conclusion: patients with hemophilia, H. pylori should not be considered as an important cause of GI bleeding. The recurrence of the infection and GI bleeding could be prevented with eradication of H.pylori. Screening tests for H. pylori would not be needed in patients with hemophilia in endemic areas.

Introduction

In Egypt, it is estimated that 5050 people with haemophilia and, 499 with vWD are registered within the six hemophilia treatment centers (www.wfh.org annual report 2013)

More than 50% of the world's population harbor Helicobacter pylori in their upper gastrointestinal tract. Infection is more prevalent in developing countries, and incidence is decreasing in Western countries [1].

According to world gastroenterology organization report in 2010, H.pylori incidence in adult Egyptians was 90% (www.worldgastroenterology.org)

It has been hypothesized that the host immunologic response against H.pylori plays a main role in determining gastric mucosal injury, through the release of cytokines and the action of auto-antibodies against H1/K1-adenosine triphosphatase of gastric epithelial cells [2].

Infection with H pylori is the main etiological factor for erosive gastritis and duodenal or gastric peptic ulcers that often complicate with life-threatening bleeding in patients with coagulation disorders [3].

The Egyptian government provides approximately 38% of healthcare costs of treating haemophilic patients (www.wfh.org annual report 2013). Most hemophilia patients are treated with plasma or cryoprecipitate, resulting in a high risk of transfusing blood-borne diseases like HIV and Hepatitis -B and -C. Factor concentrate is available only in limited quantities, and patients must travel long distances to get it.

There is a contradictory in the previous studies between prevalence of H.pylori and risk of GIT of bleeding, we prospectively investigated the prevalence of H. pylori infection in patients with Hemophilia -A or -B or VonWillebrand syndrome and its impact on risk of bleeding in those patients and compare our results with others'.

Patients and methods

This is a case control study. All participants are adult patient's visiting the hematology clinic of Kasr-Al-Aini hospital and the Egyptian society of Hemophilia. The study received research ethical committee approval from Kasr-Al-Aini medical School and all participants gave written consents. Forty patients with bleeding disorders (mean age 24); categorized as: 30 patients with Hemophilia A, 6 patients with Hemophilia-B and 4 patients with VWD. Patients who received triple therapy before or Patients with liver cirrhosis, thrombocytopenia, any platelet or vascular

Table 1: Prevalence of H.pylori and occult bleeding in patients and control.

Diagnosis	Occult Blood Positive		Occult Blood Negative	
	H.pylori Positive	H.pylori Negative	H.pylori Positive	H.pylori Negative
Hemophilia-A	5	0	15	10
Hemophilia-B	0	0	4	2
VWD	0	0	4	0
Total	5	0	23	12

defects or patients with peptic ulcer were excluded. Control group included 20 subjects (mean age 27) of the same socioeconomic level and the same exclusion criteria of the patients included in the study. Each Patient and control subject in the study were tested for H.pylori stool antigen by ELISA, This technique is non-invasive, rapid, easy-to-use, and shows good performance characteristics for diagnosis of H. pylori infections, with sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), and efficiency were 100%, 90.0%, 96.9%, 100%, and 97.6% respectively) [4]. All Patients and control subjects were tested for occult blood using guaiac-based fecal occult blood test [5]. All diet and drug precautions were applied before obtaining samples to prevent false positive results as dietary restriction of both hemoglobin and vegetable peroxidase containing substances is essential for valid screening for occult blood [6].

Statistics

Using SPSS V.16.0 for calculation of the means and z test for comparison between the prevalence of H. pylori infection among Hemophilia-A, Hemophilia-B and VonWillibrand patients and the prevalence of H.pylori infection among the control group to investigate whether there is a difference in prevalence between both groups or not.




Figure 1: Prevalence of occult bleeding in patients and control.




Figure 2: Prevalence of H.pylori in patients and control.

Comparison between the odds ratio (OR) of developing occult GI bleeding (indicted by positive guaiac test) among Hemophilia-A, Hemophilia-B and VonWillibrand patients who test positive for H.pylori and the odds ratio of developing occult GI bleeding among the control group who test positive for H.pylori to investigate whether there is a relation between the possible risk and the outcome.

Results

The patient’s group included 40 male patients (30 patients with Hemophilia-A (75%), 6 patients with Hemophilia B (15%), and 4 patients with VWD (10%)) with age ranged from 12 to 52 years (mean age 24 years).

Twenty eight out of 40 patients (70%) are H. pylori positive; and 12 out of 20 controls (60%) are H. pylori positive. Odds ratio: 1.55 95% Confidence Interval: 0.6162 to 3.9269; P = 0.3497)

Among 28 H.pylori positive patients, 5 patients tested positive for occult blood (17.9%). all patients positive for occult blood were also positive for H.pylori stool antigen. Among the 12 subjects positive for H.pylori in the control group subjects, only one tested positive for occult blood (8.3%), and he was also H.pylori positive. Odds ratio was 2.3913 (95% Confidence Interval: 0.2485 to 23.0104; P = 0.4504). None of the H.pylori negative patients or control subjects had a positive occult blood disease.

Table1 and (Figure1) demonstrate the prevalence of H.pylori and occult bleeding in patients and control, (Figure 2).

Discussion

The prevalence of H.pylori infection in patients with Hemophilia -A or -B or VonWillebrand syndrome was investigated and compared to the prevalence of H. pylori infection in normal control subjects in many studies with variable results. In our study, we didn’t find significant difference between prevalence of H. pylori among

hemophilia and VWD patients (70%) n=40 and its prevalence among normal control subjects (60%) n=20, the odds ratio is 1.55, 95% CI (0.6162 to 3.9269), z statistic 0.935, Significance level-P =0.3497). The Prevalence of H.pylori revealed by this study doesn't differ from the reported prevalence in general population: 72.38% [7]. While the odd ratio of H.pylori infection is about 1.5; It is insignificantly higher for occult bleeding detected by FOBT in absence of history of frank bleeding; Odd ratio is 2.39, 95% Confidence Interval: 0.2485 to 23.0104, P=0.4504. Our case and control were matched for geographic distribution, age, socio economic status and educational level to avoid misleading results as described previously by Wang [8]. Our results are also concomitant with Braden et al who found similar prevalence of Helicobacter pylori Infection in seventy patients with haemophilia and VWD and 100 age-related volunteers P-value were statistically insignificant [9]. Also Eleftheriadis studied thirty-seven patients with hereditary haemorrhagic diseases and 26 controls. ELISA was used to detect IgG, anti-CagA, and IgA antibodies to H.pylori in the serum and saliva. Result of this study revealed that 64.8% of the patients and 65.4% of the controls had H.pylori IgG antibodies in serum (P=0.1) [10]. Szczepanik also found that the prevalence of H. pylori infection in hemophilic patients in Poland was comparable to that in patients without coagulation disorders (49.3% vs 39% respectively P=0.11) [3].

However our results were inconsistent with the study of upper gastrointestinal bleedings in patients with hereditary coagulation disorders in Northwest of Iran. The prevalence of H.pylori infection was investigated by stool antigen test, and serum serologic tests including Immunoglobulin-G and anti-CagA. Results among 90 patients (81 men, nine women, mean age 31.30±10.72 years), 66 patients with Hemophilia-A, 10 patients with Hemophilia-B, six patients with VonWillebrand disease, five patients with platelet function disorders, and three patients with other factor deficiencies were evaluated. About 46.7% of patients in group-A, and 23.3% of patients in group-B were anti-CagA-positive (P=0.02), whereas 76.7% of patients in group-A and 51.7% of patients in group-B had H.pylori Immunoglobulin-G antibodies (P=0.02). H.pylori antigen in stool was positive in 76.7% in group-A and 55% in group-B (P=0.03) [11].

Our study also found statistically insignificant increased risk of fecal occult bleeding in absence of history of frank bleeding in patients with Hemophilia-A; Odds ratio was 2.39, 95% (Confidence Interval: 0.2485 to 23.0104, z statistic: 0.755, Significance level: P=0.4504).

Though the prevalence of H.pylori in Szczepanik et al. study were statistically insignificant however the gastrointestinal bleeding was reported in 46 patients (31.5%) with hemophilia and in two control group patients (2.0%) (P<0.0001) Gastrointestinal bleeding was significantly more frequent in patients with hemophilia infected with H. pylori (33/46; 71.7%) than in patients with no H. pylori infection (13/46; 28.3%; P=0.0002). Concluding that H.pylori infection is a risk factor for duodenal and gastric ulcer bleeding in hemophilia patients [3].

Eyster et al. detected antibodies against H.pylori in 14 (35%) of 40 subjects who had upper gastrointestinal bleeding event compared with 7 (17%) of 41 controls who were closely matched for age and other factors. Bleeding was substantially but not significantly increased (OR: 4.6; 95% CI: 0.3-83.9) with H.pylori sero-positivity [12].

Though Choe studied a group of haemophilic children but his results concluded significant role of H.pylori in inducing GIT bleeding. Helicobacter pylori infection was found in four of six (66.7%) patients with GI bleeding (3, duodenal ulcer; 1, H.pylori associated chronic gastritis). The patients with H.pylori infection had an eradication treatment of triple therapy and no recurrence happened [13].

According to our results screening for H.pylori should be routine work-up for all patients with Hemophilia-A, and all patients with positive stool antigen test should be treated immediately to prevent gastrointestinal bleeding, and to repeat testing to ensure eradication of the bacteria which may definitely lower the costs as was described by Schulman [14].

Conclusion

patients with hemophilia, H.pylori should not be considered as an important cause of GI bleeding. The recurrence of the infection and GI bleeding could be prevented with eradication of H.pylori. Screening tests for H.pylori would not be needed in patients with hemophilia in endemic areas.

References

1. Brown LM. Helicobacter pylori: Epidemiology and routes of transmission. *Epidemiol Rev.* 2000; 22: 283-297.
2. Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. *Blood.* 2001; 97: 812-814.
3. Szczepanik AB, Zaleska M, Wiszniewski A, Wislawski S, Misiak A, Maryniak R. Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding. *Haemophilia.* 2005; 11: 376-379
4. Pum Soo Kim, Jong Wook Lee, Soo Hwan Pai, et al. Detection of Helicobacter pylori Antigen in Stool by Enzyme Immunoassay. *Yonsei Med J.* 2002; 43: 7-13
5. Green BT, Rockey DC. Gastrointestinal endoscopic evaluation of premenopausal women with iron deficiency anemia. *J Clin Gastroenterol.* 2004; 38: 104-109
6. Syed AA, Khatoon BA, Silwadi MF. New reagents for detection of faecal occult blood. *J Pharm Biomed Anal.* 2001; 24: 581-586.
7. Mahmoud A Mohammad, Laila Hussein, Andy Coward, Sarah J Jackson. Prevalence of Helicobacter pylori infection among Egyptian children: Impact of social background and effect on growth. *Public Health Nutrition.* 2007; 11: 230-236.
8. Wang F, Meng W, Wang B, Qiao A. Helicobacter Pylori induced gastric inflammation and gastric cancer. *Cancer Lett.* 2014; 345: 196-202.
9. Braden B, Wenke A, Karich HJ, Dietrich CF, Scharrer I, Caspary WF. Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand's syndrome. *Helicobacter.* 1998; 3: 184-187.
10. Eleftheriadis N, Makri S, Aggouridakis C, Pithara E, Makris P. Helicobacter pylori infection in upper gastrointestinal bleeding in patients with hereditary hemorrhagic disorders. *Eur J Intern Med.* 2002; 13: 480-484.
11. Dolatkhan R, Khoshbaten M, Asvadi Kermani I, Reza Bonyadi M, Ghojzadeh M, Sanaat Z. Upper gastrointestinal bleedings in patients with hereditary coagulation disorders in Northwest of Iran: prevalence of Helicobacter pylori infection. *Eur J Gastroenterol Hepatol.* 2011; 23: 1172-1177.
12. Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ. Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. *Haemophilia.* 2007; 13: 279-286.

13. Choe BH, Kim JY, Lee JH, Kim JM, Chu MA, Cho SM. Upper gastrointestinal bleeding in children with haemophilia: a clinical significance of Helicobacter pylori infection. Haemophilia. 2010; 16: 277-280
14. Schulman S, Rehnberg AS, Hein M, Hegedus O, Lindmarker P, Hellström PM. Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. Thromb Haemost. 2003; 89: 741-746.